Comparative cardiovascular toxicity of immune checkpoint inhibitors: A real-world cohort study
The American Journal of the Medical Sciences · 2026-09 · 372 (3) · 209-217
DOI: 10.1016/j.amjms.2026.06.017 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The American Journal of the Medical Sciences, 2026-09. Verfasst von Abdul Rasheed Bahar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wayne State University, Department of Medicine, Detroit, MI, USA. Electronic address: rbahar@wayne.edu. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Myocarditis, Cardiovascular Diseases, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Immune checkpoint inhibitors (ICIs) improve cancer outcomes but can cause immune-mediated cardiovascular toxicity, including myocarditis, which is associated with substantial morbidity and mortality. Pharmacovigilance data suggest possible differences in cardiovascular risk between programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors, yet direct real-world comparisons remain limited. METHODS: We performed a retrospective cohort study using the TriNetX global research network to compare cardiovascular outcomes in adults initiating PD-1 versus PD-L1 inhibitors. Patients were compared using a 1:1 propensity score-matched design to balance baseline characteristics, with outcomes analyzed within the matched cohorts and reported as relative risks (RR) with 95% confidence intervals (CI). The primary outcome was incident myocarditis assessed at 1 year and 2 years. Secondary outcomes included pericarditis, heart failure, atrial fibrillation, ventricular arrhythmias, long QT syndrome, cardiomyopathy phenotypes, and atrioventricular block. RESULTS: After matching, 32,468 patients were included in each cohort with excellent covariate balance. PD-1 inhibitors were associated with a higher risk of myocarditis at 1 year (RR 1.49, 95% CI 1.13-1.96) and 2 years (RR 1.49, 95% CI 1.15-1.94). Pericarditis was more frequent with PD-1 inhibitors at 1 year (RR 1.28, 95% CI 1.01-1.64). Heart failure, arrhythmias, and cardiomyopathy phenotypes were largely similar between treatment groups. CONCLUSIONS: PD-1 inhibitors were associated with a higher risk of immune-mediated cardiac inflammation than PD-L1 inhibitors, while non-inflammatory cardiovascular outcomes were comparable. These findings have implications for cardio-oncology risk stratification, support closer early cardiovascular monitoring in patients initiating PD-1 therapy, and warrant prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wayne State University, Department of Medicine, Detroit, MI, USA. Electronic address: rbahar@wayne.edu.
- Wayne State University, Department of Medicine, Detroit, MI, USA.
- Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Wayne State University, Department of Medicine, Division of Cardiology, Detroit, MI, USA.
Zitieren
APA
Bahar, A. R., Bahar, Y., Elhussain, M., Kaur, P., Bolaji, O., Raheem, S., & Abidov, A. (2026). Comparative cardiovascular toxicity of immune checkpoint inhibitors: A real-world cohort study. The American Journal of the Medical Sciences, 372(3), 209-217. https://doi.org/10.1016/j.amjms.2026.06.017
Vancouver
Bahar AR, Bahar Y, Elhussain M, Kaur P, Bolaji O, Raheem S, et al. Comparative cardiovascular toxicity of immune checkpoint inhibitors: A real-world cohort study. The American Journal of the Medical Sciences. 2026;372(3):209-217. doi:10.1016/j.amjms.2026.06.017
BibTeX
@article{Bahar2026,
author = {Bahar, Abdul Rasheed and Bahar, Yasemin and Elhussain, Mohamed and Kaur, Paawanjot and Bolaji, Olayiwola and Raheem, Shaheena and Abidov, Aiden},
title = {Comparative cardiovascular toxicity of immune checkpoint inhibitors: A real-world cohort study},
journal = {The American Journal of the Medical Sciences},
year = {2026},
volume = {372},
number = {3},
pages = {209--217},
doi = {10.1016/j.amjms.2026.06.017}
}
EUVIMED